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Running Title: Chelate-free radiochemistry 
Noteworthy: 
 Effective design of multi-modality nanomedicines for nuclear/MR imaging requires new 
radiochemical methods to overcome limitations imposed by conventional prosthetic group 
and chelate-based chemistries (page 4) 
 Chelate-free methods exploit intrinsic chemical properties of nanoparticles to effect facile 
and efficient radiolabelling (Page 10) 
 Mechanistic principles underpinning seven distinct chelate-free radiolabelled methods are 
present (Page 10, Figure 3) 
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ABSTRACT 
The advent of hybrid cameras that combine magnetic resonance imaging with either single-photon 
emission computed tomography (SPECT/MRI) or positron-emission tomography (PET/MRI) has 
stimulated growing interest in developing multi-modality imaging probes. Countless options are 
available for fusing magnetically active species with positron- or gamma-ray emitting 
radionuclides. The initial problem is one of choice: which chemical systems are a suitable basis 
for developing hybrid imaging agents? Any attempt to answer this question must also address how 
the physical, chemical, and biological properties of a unified imaging agent can be tailored to 
ensure that optimum specificity and contrast is achieved simultaneously for both imaging 
modalities. Nanoparticles have emerged as attractive platforms for building multi-modality 
SPECT/MRI and PET/MRI radiotracers. A wide variety of nanoparticle constructs have been 
utilised as radiotracers but irrespective of the particle class, radiolabelling remains a key step. 
Classical methods for radiolabelling nanoparticles involve functionalisation of the particle surface, 
core or coating. These modifications typically rely on using traditional metal ion chelate or 
prosthetic group chemistries. Though seemingly innocuous, appending nanoparticles with these 
radiolabelling handles can have dramatic effects on important properties such as particle size, 
charge and solubility. In turn, alterations in the chemical and physical properties of the 
nanoparticle often have a negative impact on their pharmacological profile. A central challenge in 
radiolabelling nanoparticles is to identify alternative chemical methods that facilitate the 
introduction of a radioactive nuclide without detrimental effects on the pharmacokinetic and 
toxicological properties of the construct. Efforts to solve this challenge have generated a range of 
innovative, ‘chelate-free’ radiolabelling methods that exploit intrinsic chemical features of 
nanoparticles. Here, the chemistry of nine mechanistically distinct methods for radiolabelling 
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nanoparticles is presented. This discourse illustrates the evolution of nanoparticle radiochemistry 
from classical approaches through to modern chelate-free or intrinsic methods.  
 
KEYWORDS: nanoparticles, intrinsic radiolabelling, chelate-free, chemisorption, doping, 
isotopic exchange, cation exchange, PET/MRI. 
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INTRODUCTION 
Nanomedicine is the application of nanotechnology to diagnose or treat disease (1). In the fields 
of radiochemistry and nuclear medicine, nanoparticles are gaining prominence as platforms for 
designing hybrid imaging and therapeutic agents (2–5). In particular, nanoparticle-based 
radiotracers show promise as multi-modality SPECT/MRI and PET/MRI probes. Reasons why 
nanoparticles have attracted attention can be ascribed to their unique physical and chemical 
characteristics. Enhanced rigidity, controlled shape and size, discrete charge and electromagnetic 
properties, high surface area to volume ratios, variable porosity, resistance to metabolism in vivo, 
and tuneable chemical reactivity at the surface, on coatings and inside the particle core are just 
some of the features that demarcate nanoparticles as highly versatile scaffolds.  
 In spite of their potential, there are many questions and challenges that must be addressed 
before nanoparticle-based imaging agents can cross the divide from preclinical to clinical 
applications. From a chemical standpoint, nanoparticle-based agents are highly complex. Average 
formulations contain particles with varying chemical composition including a range of sizes, 
variable drug loading densities, and differential presentation of targeting vectors in terms of their 
number per particle as well as their spatial location and 3-dimensional orientation. For this reason, 
most measurements made using nanoparticles rely on determination of the average properties of a 
bulk sample. Such inherent variability is a potential problem for ensuring batch-to-batch 
reproducibility and can induce differences in the biological properties of nanoparticles. Attention 
must be paid to ensure that parameters including the pharmacokinetic profile, cytotoxicity, target 
affinity and specificity remains consistent between formulations (6). It is easy to appreciate that 
whilst having access to such a wide range of physical and chemical parameters is beneficial from 
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a design perspective, controlling each part of a nanoparticle system to meet stringent current Good 
Manufacturing Practice regulations is a formidable task.  
 Considering the development of a single molecular imaging probe that can be used to 
acquire nuclear and magnetic resonance images simultaneously, a number of important design 
criteria must be incorporated into the final construct.  For instance, a successful radiolabelled 
SPECT/MRI or PET/MRI probe should display high chemical, radiochemical and metabolic 
stability, low toxicity, and a favourable pharmacokinetic profile with rapid accumulation in the 
target regions matched by excretion from background organs (7). A crucial question that has yet 
to be answered in detail is how can one molecule fulfil the usual chemical and physical 
requirements of nuclear and magnetic imaging probes without compromising on target specificity 
or image contrast. This problem is highlighted by the acute difference in the normal administered 
concentrations between standard PET radiotracers and MRI contrast agents. Clinical-grade 
fluorine-18-labelled PET radiotracers have typical specific activities around 185 GBq/mol (5 
Ci/mol) with administered radioactive doses in humans around 370 to 740 MBq (10 – 20 mCi) 
(8). For an average human male (~75 kg) the administered dose of radiotracer equates to around 
~2 to 4 nmol (ca. 25 to 50 pmol/kg body weight). Typical gadolinium-based MRI contrast agents 
are administered at relatively high doses up to 0.2 mmol Gd per kg body weight (9). This represents 
a staggering ~7-orders of magnitude difference between the administered doses (and sensitivities) 
of PET and MRI imaging probes. How can a single, multi-modality PET/MRI radiotracer reconcile 
this difference in concentration whilst maintaining high contrast in MRI and avoiding target 
saturation which would reduce PET signal uptake and specificity? For a given combination of 
biological target and imaging probe, does a concentration range exist that would be an acceptable 
compromise for simultaneous PET/MRI (or SPECT/MRI)? At present, these questions have not 
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been addressed adequately. Most reports on multi-modality imaging agents have tended to 
decouple the nuclear and imaging components by showing that a single species (usually 
nanoparticles) administered at different doses can be applied for sequential SPECT/PET and MRI. 
Recent work by Zhao et al. is a notable exception (10). SPECT/MRI studies showed that a single-
dose administration of iodine-125-radiolabelled human heavy-chain ferritin nanocages (125I-M-
HFn) could image HT-29 tumours at a dose of 18.5 MBq (500 Ci) of 125I and 11.2 μg of Fe. 
However, it remains uncertain if a similar approach would be generally applicable to more diverse 
imaging biomarkers of low abundance.  
 Returning to the chemistry of nanoparticles, a practical consideration is that the 
radiolabelling step should be easy and reproducible. Ideally, radiolabelling should be performed 
in the final step of production, and addition of the radionuclide should not alter (or have known 
minimal effects on) the physical, chemical, and biological properties of the nanoparticle. These 
demanding requirements have led researchers to develop a number of innovative solutions for 
producing radiolabelled nanoparticles. In the following sections, the chemistry and application of 
nine, mechanistically distinct methods for radiolabelling different types of nanoparticles is 
explored. Classical radiolabelling methods based on modification of nanoparticles using metal ion 
chelation and prosthetic group chemistry is briefly introduced. The focus of this review is to 
illustrate how intrinsic chemical properties of nanoparticles are being harnessed by state-of-the-art 
‘chelate-free’ radiolabelling methods to produce multi-modality imaging agents (11,12).   
 
METHODS FOR RADIOLABELLING NANOPARTICLES 
The following sections provide an overview of the types of chemistry that have been used to 
radiolabel nanoparticles (11–13). 
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Classical Radiolabelling 1: Particle Surface Modifications 
Traditional approaches for radiolabelling nanoparticles rely on well-established radiochemical 
methods including the use of fluorine-18-based prosthetic groups or radiometal ion chelation. 
Here, nanoparticles are typically coated with surface reactive groups which serve a dual purpose. 
First, they allow covalent attachment of radionuclides via prosthetic groups or multidentate 
chelates. Second, they provide thermodynamically, kinetically, and metabolically stable anchors 
that ensure the radionuclide remains associated with nanoparticle in vivo. Three common examples 
of surface anchoring include thiol-mediate binding to Au-nanoparticles (14–16), silylation of 
surface hydroxyls (17), and bisphosphonate binding (18,19) to iron oxide particles (Figure 1). 
In an archetype example, Guerrero et al. (15) produced 18F-labelled Au-nanoparticles 
(AuNPs). The AuNPs were pre-functionalised with a cysteine-lysine diamino acid via covalent 
bonding of the thiolate to the Au surface. Radiolabelling was accomplished by attaching the 
fluorine-18 radiolabelled prosthetic group, N-succinimidyl-4-18F-fluorobenzoate (18F-SFB) via 
amide bond formation on the lysine side-chain. Rojas et al. (17) used a similar strategy but 
employed 3-(aminopropyl)triethoxysilane to decorate the surface of ceria (CeO2) nanoparticle with 
a primary amine that was subsequently coupled to 18F-SFB. A major drawback of this approach is 
that multiple radiolabelling steps are required, which limits overall radiochemical yields and 
specific activities. Others have sought to overcome these issues by developing a cysteamine 
derivative of 18F-2-fluoro-2-deoxy-d-glucose (18F-FDG-CA) that binds to AuNPs (14). Zhu et al. 
(16) also reported an interesting approach to make 18F-radiolabelled PEGylated AuNPs that relied 
on Si-18F bond formation. The thiol (4-(di-tert-butyl-18F-fluorosilanyl)benzenethiol (18F-SiFA-
SH) was produced via 18F/19F isotopic exchange and was subsequently conjugated to maleimido-
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AuNPs giving high radiochemical yields (60−87%). While this prosthetic group approach solves 
some of the issues associated with low RCYs, it is not clear how much of the 18F-SiFA-SH reacts 
with the maleimido group and how much reacts directly with the AuNP surface.  
In 2011, Rosales et al. used bisphosphonate chemistry to generate dual-modality 
SPECT/MRI and PET/MRI radiotracers based on conjugation of superparamagnetic iron oxide 
nanoparticles (SPIONs) with either 99mTc or 64Cu, respectively (18,19). Bisphosphonates display 
well-established affinity for several different classes of inorganic surfaces including various metal 
oxides, and hydroxyapatite crystals found in bone. Both studies followed a similar approach in 
which multidentate chelates, chosen for their selectivity toward a particular radiometal ion, were 
functionalised with a bisphosphonate group. 64Cu2+–bis(di-thiocarbamatebisphosphonate) and 
99mTc-dipicolylamine(DPA)-alendronate were conjugated Endorem (Ferumoxide or Feridex) – 
dextran-coated magnetite (Fe3O4) nanoparticles (120–180 nm diameter) approved for T2- or T2*-
contrast enhanced MRI (20). Detailed stability studies in vitro and multi-modality imaging in vivo 
confirmed the viability of bisphosphonate chemistry for radiolabelling metal oxides nanoparticles 
(21). 
 
Classical Radiolabelling 2: Particle Coating Modifications 
The second fundamental approach to radiolabelled nanoparticles involves modification to the 
particle coating. Radiolabelling reactions on particle coatings involve similar prosthetic group or 
chelate-based chemistries as described above. The key difference is that surface anchoring groups 
are not required for radiolabelling coatings. Instead, the radioactive group is introduced to the 
coating via covalent bond formation. Again, many examples have been reported and we highlight 
just two representative approaches (Figure 2).   
use only. 
by UZH Hauptbibliothek / Zentralbibliothek Zurich on January 29, 2018. For personaljnm.snmjournals.org Downloaded from 
 Page 9 
 
In 2009, Devaraj et al. reported the synthesis and multi-modal PET-computed tomography 
(PET/CT) imaging using 18F-radiolabelled cross-linked dextran iron oxide (CLIO) nanoparticles 
(22). The innovation step in radiolabelling involved derivatisation of the dextran coating with a 
reactive azide group. Subsequent copper-catalysed azide-alkyne cycloaddition ‘Click’ reactions 
using a pre-synthesised 18F-PEG3 alkyne-reagent (produced in an average 57% decay-corrected 
RCY) facilitated rapid 18F-radiolabelling of azide-functionalised CLIO nanoparticles in 40 min at 
40 C. As with most nanoparticle-based radiotracers, purification from the non-reacted 18F-PEG3-
alkyne was achieved by using a simple filtration step to give the final 18F-CLIO product in 58% 
decay corrected RCY and >99% radiochemical purity. This work showcases the potential of 
‘Click’ chemistry for producing complex radiolabelled constructs in a simple, high yielding and 
biochemically orthogonal process.  
Coating-based metal ion chelation was used by Thorek et al. to produce [89Zr]Zirconium-
desferrioxamine (DFO) labelled Feraheme® (Ferumoxytol) for use in multi-modal PET/MRI 
imaging of sentinel lymph nodes (Figure 2) (23).  In a three-step process the carboxymethyl 
dextran coating of Feraheme was functionalised with 1,2-ethylenediamine followed by 
conjugation to DFO-pBn-SCN and subsequent radiolabelling with 89Zr-oxalate to produce 89Zr-
DFO-Feraheme. Subsequent PET/MRI imaging in a transgenic mouse model of prostate cancer 
displaying elevated levels of MYC transcription factor activity showed localisation of 89Zr-DFO-
Feraheme in prostate-draining lymph nodes. Whilst this DFO-based method to radiolabel 
Feraheme with 89Zr was recently superseded by a chelate-free approach (vide infra) (24), this study 
provides a convincing demonstration of the need for multi-modal PET/MRI of deep-seated tissues 
that are difficult to identify and characterise using single modality cameras.  
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Non-classical Radiolabelling Methods 
A disadvantage of classical radiolabelling methods is that the introduction of a prosthetic group or 
metal ion chelate can have adverse effects on the pharmacokinetic and toxicity profiles of the 
nanoparticle (6,7). For this reason, efforts have been made to identify alternative methods for 
radiolabelling nanoparticles that avoid the use of often bulky, lipophilic prosthetic groups or 
chelates that alter surface charge (Figure 3).  
 
     Radiochemical Doping. This non-classical approach has previously been described as the 
addition of ‘hot-plus-cold’ precursors (11,25). A scientifically more accurate description is 
‘radiochemical doping’ – defined here as a process in which radiolabelled nanoparticles (or more 
general composites) are made via the addition of small amounts of a radionuclide during particle 
fabrication (Figure 4). The method draws on well-established protocols that have their origins in 
the Fajans-Paneth-Hahn law of radioactive co-precipitation (see Otto Hahn, ‘Applied 
Radiochemistry’ 1936, London, Oxford University Press). The law governs how a radioactive 
trace element co-precipitates in the presence of a larger amount of carrier material. If experimental 
conditions including (among others) solubility, concentrations of precipitants, ionic strength and 
counter ion identity are controlled, then it is possible to generate so-called ‘mixed crystals’ in 
which the trace radionuclide is incorporated into the crystal structure of the particulate. Notably, 
the law also states that if particles acquire a surface charge that is opposite to the charge on the 
trace element, then co-precipitation of the radioactivity will depend strongly on the conditions used 
with the tracer likely to become chemically or physically adsorbed onto the particle surface (vide 
infra the sections on chemisorption and physisorption).  
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 Numerous reports using co-precipitation have proven that radiochemical doping is an 
effective means for generating a wide range of radiolabelled nanoparticles involving different core 
materials and radionuclides. Radiochemical doping has been achieved using 64Cu (26–30), 65Zn 
(31),  68Ga (32), 109Cd (33), 111In (31,34), 141Ce (31), 153Sm (35) and 198Au (36,37) radionuclides 
to produce multi-modality particles.  
 In a state-of-the-art example of homo-radionuclide doping, Black et al. produced a range 
of shape- and size-controlled PEGylated gold nanostructures loaded with 198Au (t1/2 = 2.69 d; – 
100%). All nanoparticles were of a similar size but the authors produced different nanostructures 
including nanospheres, nanodiscs, nanorods, and cubic nanocages. A combination of ex vivo 
biodistribution data and in vivo SPECT coupled with Cerenkov luminescent imaging (CLI) and 
computed tomography (CT) was used to measure tumour localisation in mice bearing a murine 
EMT6 breast carcinoma model. Remarkably, pharmacokinetic profiles and intratumoural studies 
showed that radiotracer distribution was heavily dependent on the particle shape. The 198Au-
nanospheres showed the longest blood pool residence time and the highest uptake in tumours 
reaching 23.2 %ID/g at 24 h. Understanding how the physical shape of nanoparticles influences 
their behaviour in vivo is an emerging frontier in nanoscience that will likely impact future design 
of multi-modality radiotracers (38).  
 It is important to note that, while radiochemical doping is a fairly general synthetic strategy, 
not all metal ions and metal-based nanoparticles are compatible. For example, Zeng et al. studied 
the properties of 111In- and 57Co-doped PEGylated Fe3O4 nanoparticles. Radiochemical stability 
measurements found that 111In-doped nanoparticles remained intact at pH2. However, 21.0% of 
the radioactivity was leached from the 57Co-doped nanoparticles after dialysis for 24 h in water. 
The difference in the dopant leaching was attributed to the different solubility products of the 
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corresponding hydroxides (210-16 for Co(OH)2 and 1.310-37 for In(OH)3). This work provides 
important lessons that dopant-nanoparticle chemistry must be matched, and that careful stability 
measurements should always be performed prior to conducting biological assays in vitro and in 
vivo. 
 
     Physisorption. While doping involves incorporation of the tracer into the core of the 
nanoparticle crystal, most other non-classical nanoparticle radiolabelling methods make use of 
surface-based chemistry. Physical adsorption (physisorption) is a process by which small 
molecules or ions interact and associate with a molecular surface via electrostatic attraction or van 
der Waals interactions. The key feature of physisorption is that no discrete covalent or dative 
covalent bond is made between the species binding to the particle and the surface itself. Solid 
nanoparticles dispersed as a colloid in solution typically acquire a surface charge known as the 
electric double layer potential (Figure 5). This charged layer is often characterized by the measured 
zeta potential (in units of mV) with higher net charges (either positive or negative) correlating with 
increased stability of the colloid in solution and lower net charges favouring coagulation or 
flocculation. The zeta potential also affects absorption, distribution, metabolism, excretion and 
toxicological (ADME-tox) properties of nanoparticles (39,40). 
 From a radiolabelling perspective, species (ions) that acquire the opposite charge to that of 
the nanoparticle surface can become immobilised in the stationary layer between the particle 
surface and the dispersed medium. To the best of our knowledge, there are no specific reports of 
radiolabelling nanoparticles via a physisorption process. However, the absence of data likely 
reflects our limited mechanistic knowledge on the interactions between radiometal ions with 
particle surfaces. Many nanoparticle-based systems acquire a negative zeta potential, and hence, 
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it is intuitive that positively charge metal cation species can potentially form a tight ion pair with 
the surface and become ‘trapped’ electrostatically in the immobile region. Further studies are 
required to elucidate if physisorption is a viable method for radiolabelling nanoparticles.  
 
     Direct Chemisorption. Arguably the most versatile and promising new method for 
radiolabelling a broad scope of nanoparticles involves direct chemical bond formation between the 
radionuclide and the particle surface (Figure 3). In surface chemistry, this mechanism is called 
chemisorption. The approach was pioneered by the group of Weibo Cai and co-workers (41–48). 
The concept has recently been generalised, first by our group (24) for metal ions from across the 
Period Table, and subsequently by others for different classes of nanoparticle (49–52). 
 In 2013, Chen et al. reported an intriguing study in which the well-known affinity of As3+ 
and As5+ ions for the surface of magnetite (Fe3O4) was exploited to develop a novel chelate-free 
approach for producing *As-radiolabelled superparamagnetic iron oxide nanoparticles (*As-
SPIONs, where * = 71, 72, 74, 76) as potential PET/MRI imaging agents (41). The high affinity 
of arsenic ions for Fe3O4 has been attributed to direct chemisorption in which As3+O3 trigonal 
pyramids or As5+O4 tetrahedra occupy vacant FeO4 tetrahedral sites on the octahedrally terminated 
{111} surface of the magnetite nanoparticles. Control studies using citrate-capped copper sulfide 
(CuS) nanoparticles or SPIONs coated with dense silica (dSiO2) showed no appreciable 
radiolabelling confirming that the adsorption process involved specific chemical interactions with 
the magnetite surface. Further studies in mice demonstrated that the PEGylated compounds, *As-
SPION-PEG, were suitable radiotracers for mapping lymph-node drainage with PET/MRI. It is 
noteworthy that prior to the development of this chelate-free method, chemical options for 
radiolabelling molecules with *Asn+ were restricted to As-thiolate chelation. Follow-up studies 
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have found that direct chemisorption is a viable synthetic route for producing multi-modality 
radiotracers using different radionuclides (69Ge, 64Cu, 89Zr and recently 45Ti) and nanoparticles 
including SPIONs, iron oxide-coated MoS2 nanosheets, mesoporous silica nanoparticles (MSNs), 
Gd2O2S:Eu nanophosphors, and nanographene.  
 In 2015, our group demonstrated the generality of chelate-free chemisorption 
radiolabelling of iron oxide-based nanoparticles (24). Non-radioactive induction-coupled plasma 
mass spectrometry studies found that chemisorption could be used to label Feraheme (FH) 
nanoparticles with different metal ions including p-block In3+, first row d-block Mn2+, Co2+, Cu2+ 
and Zn2+, second row Zr4+, and f-block lanthanide ions like Eu3+ and Tb3+ (Figure 6A). 
Radiolabelling experiments using 64CuCl2, 111InCl3 and 89Zr-oxalate demonstrated that by using 
the same reaction conditions radiolabelled 64Cu-FH, 111In-FH and 89Zr-FH could be produced in 
66±6%, 91±2% and >95% decay corrected radiochemical yields, respectively. This is a remarkable 
result given the differences in charge, ionic radius, and chemical requirements of these metal ions. 
In vitro characterisation experiments found that the FH nanoparticles were physically and 
chemically unchanged after radiolabelling and that the radioactivity remained tightly bound to the 
particles even in the presence of standard chelate challenge or serum stability assays. In most 
instances, the precise nature and location of the metal ion binding to the particle is not known. 
However, electron paramagnetic resonance (EPR) studies using natural 63/65Cu-FH provided a 
strong indication that the metal ions are surface bound and do not interact with the core crystal 
structure of the magnetite SPIONs. Further studies are required to elucidate the precise nature of 
the chemical interactions between different metal ions and different surfaces. PET/MRI and CT 
imaging experiments were performed using 89Zr-FH which showed that the radiotracer is 
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potentially useful for monitoring acute phase response inflammation (via accumulation in 
macrophages) or for detecting biochemical changes in the lymphatic system (Figures 6B and 6C).  
 Subsequent work by Shaffer et al. also showed that direct chemisorption using 64Cu, 68Ga, 
89Zr, 90Y, 111In and 177Lu was applicable for radiolabelling silica nanoparticles (49). Further 
examples of direct chemisorption include the interaction of 89Zr4+ ions with phosphate groups of 
pre-formed liposomes (53), 18F-radiolabelling of Al2O3-coated MnFe2O4 and Fe3O4 nanoparticles 
(54), 18F-radiolabelling of rare-earth nanoparticles (55,56) and [11C]methyl iodide radiolabelling 
of carboxylate- and amine-coated iron oxide nanoparticles (57). Collectively, reports on 
radiolabelling via direct chemisorption offer general lessons that, i) chelate-free methods typically 
do not disrupt the physical and biochemical properties of the nanoparticle, and ii) the radionuclide-
surface chemistry must be well-matched for specific and stable bonding to occur.  
 
     Isotope Exchange. Substitution of a non-radioactive nuclide for a chemically equivalent 
radioactive nuclide is termed isotopic exchange. The method is most frequently encountered in the 
chemistry of 19F/18F-exchange for radiolabelling small-molecules. A limited number of studies that 
fall into this category of non-classical radiolabelling of nanoparticles have been reported, but the 
approach is feasible. For example, Cui et al. (56) and Sun et al. (55) evaluated the properties of 
various 18F-radiolabelled nanoparticles that incorporate NaYF4. At present, it remains unclear if 
the high affinity of 18F-fluoride anions for NaYF4 surfaces involves a mechanistic addition 
(chemisorption) or a substitution (isotopic exchange). Nevertheless, as the diversity of 
nanoparticle-based radiotracers expands, simple isotopic exchange reactions may become more 
prevalent routes for radiolabelling. 
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     Cation Exchange. The concept of cation exchange is an established process in nanocrystal 
synthesis and materials science (58). Mechanistically, cation exchange is related to the 
aforementioned isotopic exchange in that a substitution reaction occurs either on the surface or 
inside the core of the nanocrystal (Figure 3). The key difference is that for cation exchange, the 
incoming radionuclide and the displaced cation can be chemically distinct. Perhaps the term 
‘heteronuclide exchange’ is a more appropriate since it encompasses possible substitution of 
different atoms, irrespective of the charge. To the best of our knowledge, only two reports that 
have utilized cation exchange for radiolabelling nanoparticles.  
  Sun et al. produced 64Cu-radiolabelled CdSe/ZnS quantum dots (QDs) via M2+ cation 
exchange (59). The process was described as ‘doping’ but since the QDs were pre-fabricated prior 
to radiolabelling, the mechanism is more accurately classified as cation exchange or 
chemisorption. Interestingly, incorporation of 64Cu-radionuclides into the QDs induced the 
particles to ‘auto-fluoresce’ after excitation from the emitted Cerenkov radiation. Subsequent 
measurements in mice bearing U87MG glioblastoma model showed specific accumulation of 
64Cu-QDs in the tumours and provided evidence that optical luminescence imaging can be fused 
with nuclear imaging in the form of multi-modality PET/CLI.  
 Separately, Sun et al. (60) reported that cation exchange could be used to radiolabel 
different mixed core-shell nanoparticles based on NaLuF4:Yb,Gd,Tm composites with 153Sm. This 
example lies at the borderline between cation exchange and radiochemical doping (35). The 
authors produced a composite nanoparticle consisting of a NaLuF4:Yb,Tm coated in a secondary 
shell of NaGdF4(153Sm). A homogenous solution of GdCl3 and 153SmCl3 was added to pre-formed 
nanocrystals of NaLuF4 to form a radiolabelled coating using forcing conditions. Subsequent 
annealing at 300 C and re-dispersion in citrate produced cit-NaLuF4:Yb,Tm@NaGdF4(153Sm) 
use only. 
by UZH Hauptbibliothek / Zentralbibliothek Zurich on January 29, 2018. For personaljnm.snmjournals.org Downloaded from 
 Page 17 
 
nanocrystals. While successful in the production of a multi-modality optical/SPECT/CT imaging 
agent, such harsh radiolabelling conditions will limit potential biomedical applications of this 
method.  
 
     Particle Beam or Reactor Activation. An interesting concept toward radiolabelled nanoparticles 
is to pre-synthesise the non-radioactive variant and then use particle beam or reactor-based 
activation to transmute an atom in situ (5) (Figure 3). Both neutron (61,62) and proton (63,64) 
activations have been reported to produce radiolabelled nanoparticles via 18O(p,n)18F, 16O(p,)13N, 
and 165Ho(n,)166Ho transmutation. For example, Munaweera et al. produced 166Ho-radiolabelled 
garnet nanoparticles loaded with various platinum-based chemotherapeutics (62). The magnetic 
166Ho-HolG-Pt were selectively delivered to a lung tumour model using an external magnetic field. 
Statistically significant decreases in tumour burden were noted for groups treated with both active 
Pt complexes and the application of an external magnetic field versus controls. While this 
inorganic system shows promise, lack of stability of organic materials in the particle beam will 
likely limit more wide-spread use of this method. 
 
     Cavity Encapsulation. The final method involves trapping a radioactive species inside the 
cavity of a nanoparticle. The process relies on a physical encapsulation which can also be described 
as a ‘mechanical bond’. Classic examples of systems that allow for drug encapsulation include 
liposomes (65) and single-walled carbon nanotubes (SWCNTs) (66) (Figure 7). While 
incorporation of radiometal ions into the aqueous phase core of liposomes is a well-established 
method for producing radioscintigraphy and SPECT imaging agents using 99mTc, insertion of 
radionuclides into nanotubes is more challenging. In 2014, Cisneros et al. reported methods for 
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the stable, simultaneous confinement of both Gd3+ ions and 64Cu2+ ions into ultra-short SWCNTs 
(66). Radiolabelled nanotubes were stabilised using surfactants and although some 64Cu was 
removed by serum challenge, the constructs were sufficiently stable to allow evaluation of the 
pharmacokinetic profiles using PET/MRI. Since SWCNTs have a high loading capacity, and the 
Gd3+ ions and radionuclides contained within are shielded from the biological environment, cavity 
encapsulation offers a potential solution for solving the concentration problem between PET and 
MRI without compromising biological specificity.  
 
CONCLUSIONS 
Emerging methods that exploit the intrinsic chemical and physical properties of nanoparticles have 
sparked a revolution in surface-based radiochemistry. While nanoparticles remain inherently 
challenging systems, they present unparalleled opportunities for developing multi-modality 
radiotracers. A switch to chelate-free radiochemistry has broadened the tools available to 
radiochemists, narrowing the gap between academic curiosity and clinical translation. Future 
advancements will likely ultilise intrinsically labelled nanomedicines as multi-modal imaging 
agents that target specific disease biomarkers.  
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Figure 1. Illustration of some of classical, surface-based methods that have been used to 
radiolabelled nanoparticles. 
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Figure 2. Two prominent examples of classic coating-based radiolabelling methods. 
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Figure 3. Illustration of the diversity of emerging chelate-free methods that are being developed 
for radiolabelling different nanoparticles.  
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Figure 4. Schematic showing the concept of radiochemical doping during nanoparticle fabrication.  
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Figure 5. Schematic showing the distribution of charged ions around the surface of a nanoparticle 
in solution.  
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Figure 6. (A) Temperature-dependent induction-coupled plasma mass spectrometry data showing 
that metal ion salts from across the Periodic Table can be used in chelate-free labelling. PET/CT 
images showing the uptake of 89Zr-FH in (B) in an acute phase response inflammation model, and 
(C) normal lymph nodes.  
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Figure 7. Schematic showing cavity encapsulation of a radiolabel inside liposomes and single-
walled carbon nanotubes. The underlying liposome figure has been reproduced under a Creative 
Commons Attribution: Vladimir P. Shirinsky, http://eng.thesaurus.rusnano.com/wiki/article1075. 
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